Cargando…
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
PURPOSE: In cancer patients, tumor gene mutations contribute to drug resistance and treatment failure. In patients with metastatic breast cancer (MBC), these mutations increase after multiline treatment, thereby decreasing treatment efficiency. The aim of this study was to evaluate gene mutation pat...
Autores principales: | Hu, Zhe-Yu, Xie, Ning, Tian, Can, Yang, Xiaohong, Liu, Liping, Li, Jing, Xiao, Huawu, Wu, Hui, Lu, Jun, Gao, Jianxiang, Hu, Xuming, Cao, Min, Shui, Zhengrong, Xiao, Mengjia, Tang, Yu, He, Qiongzhi, Chang, Lianpeng, Xia, Xuefeng, Yi, Xin, Liao, Qianjin, Ouyang, Quchang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020712/ https://www.ncbi.nlm.nih.gov/pubmed/29807833 http://dx.doi.org/10.1016/j.ebiom.2018.05.015 |
Ejemplares similares
-
FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients
por: Xie, Ning, et al.
Publicado: (2020) -
Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
por: Zhou, Dabo, et al.
Publicado: (2019) -
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
por: Liu, Binliang, et al.
Publicado: (2023) -
Corrigendum to “Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer” [Translational Oncology (2019) 12, 764–774]
por: Zhou, Dabo, et al.
Publicado: (2021) -
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies
por: Tang, Yu, et al.
Publicado: (2020)